铂类化疗-话题@MedSci

vue-cli-subapp

#铂类化疗#

0篇内容 | 1004人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2251485, encodeId=d231225148544, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a> <a href='/topic/show?id=90c21089425f' target=_blank style='color:#2F92EE;'>#铂类化疗#</a> <a href='/topic/show?id=b81b105416e7' target=_blank style='color:#2F92EE;'>#莫博替尼#</a>, objectTitle=JCO | EXCLAIM-2试验：莫博替尼一线治疗EGFR外显子20插入突变阳性NSCLC的III期研究, objectType=article, longId=862753, objectId=8843862e534d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240726/1721960745928_92910.png, objectUrl=/article/show_article.do?id=8843862e534d, replyNumber=0, likeNumber=18, createdTime=2025-02-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=8843862e534d, moduleTitle=JCO | EXCLAIM-2试验：莫博替尼一线治疗EGFR外显子20插入突变阳性NSCLC的III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8843862e534d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226100, encodeId=43592226100b5, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=d289389808b' target=_blank style='color:#2F92EE;'>#同源重组#</a> <a href='/topic/show?id=90c21089425f' target=_blank style='color:#2F92EE;'>#铂类化疗#</a>, objectTitle=约30%胃癌患者检出同源重组（HR）基因变异，能否预测一线铂类化疗疗效？, objectType=article, longId=843515, objectId=2adb843515d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720959810929_5579292.jpg, objectUrl=/article/show_article.do?id=2adb843515d3, replyNumber=0, likeNumber=80, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2adb843515d3, moduleTitle=约30%胃癌患者检出同源重组（HR）基因变异，能否预测一线铂类化疗疗效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2adb843515d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219033, encodeId=d6532219033af, content=<a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a> <a href='/topic/show?id=ef013e1416c' target=_blank style='color:#2F92EE;'>#原发灶不明肿瘤#</a> <a href='/topic/show?id=90c21089425f' target=_blank style='color:#2F92EE;'>#铂类化疗#</a> <a href='/topic/show?id=427d11e64343' target=_blank style='color:#2F92EE;'>#分子引导治疗#</a>, objectTitle=肿瘤都找不到，还能抗癌？《柳叶刀》：近2年疾病无进展，新疗法已写入指南！, objectType=article, longId=838027, objectId=453583802e58, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240708/1720420953692_92910.png, objectUrl=/article/show_article.do?id=453583802e58, replyNumber=0, likeNumber=116, createdTime=2024-08-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=453583802e58, moduleTitle=肿瘤都找不到，还能抗癌？《柳叶刀》：近2年疾病无进展，新疗法已写入指南！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=453583802e58)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176200, encodeId=a37021e620019, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a> <a href='/topic/show?id=90c21089425f' target=_blank style='color:#2F92EE;'>#铂类化疗#</a>, objectTitle=NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长, objectType=article, longId=806193, objectId=8c268061935d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=8c268061935d, replyNumber=0, likeNumber=124, createdTime=2023-12-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8c268061935d, moduleTitle=NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c268061935d)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

非小细胞肺癌 Selpercatinib 铂类化疗

2023-12-20发表于上海

梅斯管理员

#NSCLC# #III期研究# #铂类化疗# #莫博替尼#

JCO | EXCLAIM-2试验：莫博替尼一线治疗EGFR外显子20插入突变阳性NSCLC的III期研究

2025-02-11发表于陕西省

梅斯管理员

#胃癌# #同源重组# #铂类化疗#

约30%胃癌患者检出同源重组（HR）基因变异，能否预测一线铂类化疗疗效？

2024-09-16发表于上海

梅斯管理员

#靶向治疗# #原发灶不明肿瘤# #铂类化疗# #分子引导治疗#

肿瘤都找不到，还能抗癌？《柳叶刀》：近2年疾病无进展，新疗法已写入指南！

2024-08-07发表于上海

梅斯管理员

#非小细胞肺癌# #Selpercatinib# #铂类化疗#

NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长

2023-12-20发表于上海